Viracta is committed to advancing new medicines based on its viral activation therapy approach to benefit patients with viral-associated cancers and other serious diseases. Viracta’s proprietary platform is a highly targeted combination therapy approach for virus-associated malignancies. The Company's initial focus is on cancers associated with the Epstein Barr Virus. Viracta will also expand into additional applications to utilize this approach to benefit patients with a range of virus-associated diseases.
|HQ||San Diego, US||Map|
|Employees (est.) (May 2019)||12||(+10%)|
Viracta Therapeutics total Funding
Viracta Therapeutics latest funding size
Time since last funding
|2 years ago|
Viracta Therapeutics investors
|Wicklow Capital, Latterell Venture Partners, Forward Ventures, NantKwest|
Viracta Therapeutics has 170 Twitter Followers. The number of followers has increased 0.1% month over month and increased 4% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Viracta Therapeutics founded?
Viracta Therapeutics was founded in 2016.
How many employees does Viracta Therapeutics have?
Viracta Therapeutics has 12 employees.
Who are Viracta Therapeutics competitors?
Competitors of Viracta Therapeutics include Dicerna Pharmaceuticals, Urogen Pharma and Fennec Pharma.
Where is Viracta Therapeutics headquarters?
Viracta Therapeutics headquarters is located at La Jolla Commons, 4747 Executive Dr #700, San Diego.
Where are Viracta Therapeutics offices?
Viracta Therapeutics has an office in San Diego.
How many offices does Viracta Therapeutics have?
Viracta Therapeutics has 1 office.